🇺🇸 FDA
Patent

US 6664263

1,8-naphthalimide imidazo{4,5,1-de}acridones with anti-tumor activity

expired A61KA61K31/4745A61K31/496

Quick answer

US patent 6664263 (1,8-naphthalimide imidazo{4,5,1-de}acridones with anti-tumor activity) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Dec 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Dec 16 2003 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/4745, A61K31/496, A61K31/506, A61P